ELICIO THERAPEUTICS INC (ELTX) — insider trading
Health Care · NASDAQ
ELICIO THERAPEUTICS INC (ELTX) has 24 reported SEC Form 4 insider transactions in our data (latest 2026-08-31).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Nissenson Allen | Director | Grant / award / vesting (derivative) | 21,750 | — | $0 | Form 4 |
| 2026-08-31 | Venkatesan Jay | Director | Grant / award / vesting (derivative) | 21,750 | — | $0 | Form 4 |
| 2026-08-31 | WILSON KAREN J | Director | Grant / award / vesting (derivative) | 21,750 | — | $0 | Form 4 |
| 2026-08-31 | RUFFOLO ROBERT R | Director | Grant / award / vesting (derivative) | 21,750 | — | $0 | Form 4 |
| 2026-08-31 | Chudnovsky Yekaterina | Director, 10% owner | Grant / award / vesting (derivative) | 21,750 | — | $0 | Form 4 |
| 2026-08-31 | Ashe Carol Gail | Director | Grant / award / vesting (derivative) | 21,750 | — | $0 | Form 4 |
| 2026-08-31 | ADAMS JULIAN | Director | Grant / award / vesting (derivative) | 21,750 | — | $0 | Form 4 |
| 2026-07-16 | Connelly Robert | Director, Officer (CEO, President and Director) | Grant / award / vesting (derivative) | 186,944 | — | $0 | Form 4 |
| 2026-07-16 | Shah Preetam | Officer (See Remarks) | Grant / award / vesting (derivative) | 60,833 | — | $0 | Form 4 |
| 2026-07-16 | DeMuth Peter | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 52,832 | — | $0 | Form 4 |
| 2026-07-16 | Haqq Christopher | Officer (See Remarks) | Grant / award / vesting (derivative) | 64,643 | — | $0 | Form 4 |
| 2026-02-02 | Haqq Christopher | Officer (See Remarks) | Grant / award / vesting (derivative) | 50,900 | — | $0 | Form 4 |
| 2026-02-02 | Haqq Christopher | Officer (See Remarks) | Grant / award / vesting | 25,400 | — | $0 | Form 4 |
| 2026-02-02 | DeMuth Peter | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 41,600 | — | $0 | Form 4 |
| 2026-02-02 | DeMuth Peter | Officer (Chief Scientific Officer) | Grant / award / vesting | 20,800 | — | $0 | Form 4 |
| 2026-02-02 | Shah Preetam | Officer (See Remarks) | Grant / award / vesting (derivative) | 47,900 | — | $0 | Form 4 |
| 2026-02-02 | Shah Preetam | Officer (See Remarks) | Grant / award / vesting | 24,000 | — | $0 | Form 4 |
| 2026-02-02 | Connelly Robert | Director, Officer (CEO, President and Director) | Grant / award / vesting (derivative) | 147,200 | — | $0 | Form 4 |
| 2026-02-02 | Connelly Robert | Director, Officer (CEO, President and Director) | Grant / award / vesting | 73,600 | — | $0 | Form 4 |
| 2025-12-09 | DeMuth Peter | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 362 | — | $0 | Form 4 |
| 2025-12-09 | DeMuth Peter | Officer (Chief Scientific Officer) | Option exercise / conversion | 362 | $4.41 | $1.6K | Form 4 |
| 2025-06-03 | Chudnovsky Yekaterina; GKCC, LLC | Director, 10% owner | Grant / award / vesting (derivative) | 103,225 | — | $0 | Form 4 |
| 2025-05-19 | Nissenson Allen | Director | Grant / award / vesting (derivative) | 7,900 | — | $0 | Form 4 |
| 2025-05-19 | Ashe Carol Gail | Director | Grant / award / vesting (derivative) | 7,900 | — | $0 | Form 4 |
Ask the chat about ELTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ELICIO THERAPEUTICS INC (ELTX).
Last updated 2026-08-31 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.